These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday

Motley Fool2021-06-30

The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT. The Nasdaq is known ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

KryZ
2021-06-30
KryZ
Biotechs are risky plays but can hit jackpot if lucky!
Bull1973
2021-06-30
Bull1973
Like and comment pls comment
- adamkok94:
  K
witnessing
2021-06-30
witnessing
?
- Bull1973:
  Great day
Jasonyoyoo
2021-06-30
Jasonyoyoo
Very good
Jx1111
2021-06-30
Jx1111
Good
iawang
2021-06-30
iawang
Commenting now
- EriViL:
  Like

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100317118?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-30 13:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100317118","market":"us","top_or_hot":-1,"title":"These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday","media":"Motley Fool","content":"<div>\n<p>The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.\nThe Nasdaq is known ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 13:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.\nThe Nasdaq is known ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CERE","symbol_name":"Cerevel Therapeutics Holdings, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/","article_id":"1100317118","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100317118","pubTimestamp":1625030487,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The ind","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc.","SNSE":"Sensei Biotherapeutics, Inc."},"translate_title":"这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CERE":0.9,"SNSE":0.9},"content_text":"The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.\nThe Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.Cerevel Therapeutics Holdings(NASDAQ:CERE)got a nice push higher, but investors in Sensei Biotherapeutics(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.\nCerevel serves up an early win\nShares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.\nCerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.\nThe company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.\nCerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.\nA disappointment for Sensei\nShares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.\nSensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.\nUnfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.\nSensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.\nThe biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":153580751,"gmtCreate":1625034591673,"gmtModify":1703850604937,"author":{"id":"3574671514316116","authorId":"3574671514316116","name":"KryZ","avatar":"https://community-static.tradeup.com/news/8657f0cc14de942f5047d99219cd2d75","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574671514316116","authorIdStr":"3574671514316116"},"htmlText":"Biotechs are risky plays but can hit jackpot if lucky!","listText":"Biotechs are risky plays but can hit jackpot if lucky!","text":"Biotechs are risky plays but can hit jackpot if lucky!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153580751","repostId":1100317118,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153516134,"gmtCreate":1625034133228,"gmtModify":1703850598077,"author":{"id":"3584680402793671","authorId":"3584680402793671","name":"Bull1973","avatar":"https://static.tigerbbs.com/866d29bf88ff7363d121a5ccc6028aae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3584680402793671","authorIdStr":"3584680402793671"},"htmlText":"Like and comment pls comment&nbsp;","listText":"Like and comment pls comment&nbsp;","text":"Like and comment pls comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153516134","repostId":1100317118,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5078129,"gmtCreate":1625034927872,"gmtModify":1663230323842,"authorId":3555618838812838,"author":{"id":3555618838812838,"idStr":"3555618838812838","authorId":3555618838812838,"name":"adamkok94","avatar":"https://static.tigerbbs.com/f265cbc13af25fd5c5d975aafa794402","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153516134,"type":1,"supId":0,"prevId":0,"content":"K","text":"K","html":"K"}],"langContent":"EN"},{"id":153532457,"gmtCreate":1625033362779,"gmtModify":1703850587692,"author":{"id":"4087930869469570","authorId":"4087930869469570","name":"witnessing","avatar":"https://static.tigerbbs.com/836309f4ad7402c079c16d881c9aff9f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4087930869469570","authorIdStr":"4087930869469570"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153532457","repostId":1100317118,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5078064,"gmtCreate":1625034150527,"gmtModify":1663230323562,"authorId":3584680402793671,"author":{"id":3584680402793671,"idStr":"3584680402793671","authorId":3584680402793671,"name":"Bull1973","avatar":"https://static.tigerbbs.com/866d29bf88ff7363d121a5ccc6028aae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153532457,"type":1,"supId":0,"prevId":0,"content":"Great day","text":"Great day","html":"Great day"}],"langContent":"EN"},{"id":153504624,"gmtCreate":1625031390668,"gmtModify":1703850560890,"author":{"id":"3577446101921159","authorId":"3577446101921159","name":"Jasonyoyoo","avatar":"https://static.tigerbbs.com/0f3ffe1c770fb88e35b82d572b5cdeb4","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3577446101921159","authorIdStr":"3577446101921159"},"htmlText":"Very good&nbsp;","listText":"Very good&nbsp;","text":"Very good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153504624","repostId":1100317118,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153506508,"gmtCreate":1625031172404,"gmtModify":1703850556674,"author":{"id":"3570771243125883","authorId":"3570771243125883","name":"Jx1111","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3570771243125883","authorIdStr":"3570771243125883"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153506508","repostId":1100317118,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153501672,"gmtCreate":1625031024196,"gmtModify":1703850553589,"author":{"id":"3574379344635374","authorId":"3574379344635374","name":"iawang","avatar":"https://community-static.tradeup.com/news/090ab974c3086142d05263cd704a81b6","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"3574379344635374","authorIdStr":"3574379344635374"},"htmlText":"Commenting now","listText":"Commenting now","text":"Commenting now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/153501672","repostId":1100317118,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5077844,"gmtCreate":1625031958181,"gmtModify":1663230323734,"authorId":3577087216911488,"author":{"id":3577087216911488,"idStr":"3577087216911488","authorId":3577087216911488,"name":"EriViL","avatar":"https://static.tigerbbs.com/f37d027290c1cdf3fa6cdba6443077c6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153501672,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":67,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100317118"}